What is Harrow's accrual of milestone payment?

Harrow (HROW) reported accrual of milestone payment of $1.75M in Q4 2025.

What does accrual of milestone payment mean?

Reflects the recognition of liabilities for future payments contingent upon achieving specific operational or clinical milestones. This metric is critical for assessing future cash obligations related to research, development, or licensing agreements.

Harrow HROW Accrual Of Milestone Payment

Accrual Of Milestone Payment at other companies

Catalyst PharmaceuticalCPRX

$3.13M—

CelcuityCELC

$5M—

InsmedINSM

$15M—

Dianthus TherapeuticsDNTH

$15M0.0%

MannkindMNKD

$2M-20.6%

InsmedINSM

$15M—

Other financials

Income statement

See full

Revenue$44.2M-7.6%

Gross profit$27.0M-16.3%

Operating income-$22.1M-96.6%

Net income-$27.6M-55.2%

EPS (diluted)-$0.74-48.0%

Balance sheet

See full

Cash & equivalents$94.6M+41.8%

Total debt$308.6M-32.9%

Total equity$28.7M-49.1%

Total assets$419.5M+15.2%

Cash flow

See full

Operating cash flow-$9.0M-146%

CapEx$194.0K+14.1%

Free cash flow-$9.2M-147%

Valuation

See full

Market cap$1.59B+38.4%

Enterprise value$1.8B+13.8%

P/S5.9×+0.5×

Profitability

See full

Gross margin74.1%-0.4pp

Operating margin7.3%+5.2pp

Net margin-19.8%+18.0pp

FCF margin5.7%+5.0pp

Returns & leverage

See full

Return on equity-50%+17.5pp

Debt / equity10.7×+2.6×

Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept HROW:AccrualOfMilestonePayment.

The official record: Harrow’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's accrual of milestone payment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Harrow's accrual of milestone payment?: Harrow (HROW) reported accrual of milestone payment of $1.75M in Q4 2025.
What does accrual of milestone payment mean?: Reflects the recognition of liabilities for future payments contingent upon achieving specific operational or clinical milestones. This metric is critical for assessing future cash obligations related to research, development, or licensing agreements.